DUBLIN, June 10, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Global Hypophosphatemia Drugs Market Insights, Opportunities, Analysis, Market Shares and Forecast 2016 - 2022" report to their offering.
Hypophosphatemia predicted in patients who have an antiquity of starvation, anorexia/bulimia, alcoholism. Adequate cure comprises phosphate supplements along with feeding and care to causal eating disorders or substance exploitation. The global hypophosphatemia drugs market is driven by increasing aging population.
The global Hypophosphatemia drugs market is estimated to see new heights during the forecasted period. The stringent government regulations and presence of alternatives are hampering the growth of Hypophosphatemia drugs in the global market. The untapped APAC region is creating the huge opportunities for the forecasted period in global Hypophosphatemia drugs market.
The Hypophosphatemia drugs is segmented on the basis of application, medical care and geography. The application segment is segmented into mineral supplements, vitamin D preparation and calcimimetic drugs. Medical care segment is further segmented into cause, severity and duration.
The global Hypophosphatemia drugs market is driven by the presence of some the prominent players in the market, Biotech Pharmacal, Cipla, DM Pharma, DSM, Johnson & Jhonson, Pfizer, Sun Pharm Inc. and UltraGenyx.
Key Topics Covered:
1. Introduction
1.1. Executive Summary
1.2. Estimation Methodology
2. Market Overview
2.1. Market Definition And Scope
2.2. Key Findings
2.3. Parametric Analysis
2.4. Key Market Insights
2.5. Competitive Landscape
2.6. Porter's Five Force Model
2.7. Key Buying Criteria
2.8. Strategic Recommendation
2.9. Strategic Conclusions
3. Market Determinants
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Market Challenges
3.5. Parent Market
3.6. Competitors Market
3.7. Alternative Market
4. Market Segmentation
4.1. By Application
4.2. By Medical Care
5. Geographical Analysis
6. Company Profiling: - (Over, Scot Analysis, Strategic Review)
- Biotech Pharmacal
- Bruno Farmaceutici Spa
- Cipla
- DM Pharma
- DSM
- Fermenta Biotech Ltd.
- Johnson & Johnson
- Moore Drugs Co.
- Pfizer
- Roche
- Siemens
- Sun Pharm Inc
- Ultragenyx
- Upjohn
- Zeria Pharmaceutical
For more information visit http://www.researchandmarkets.com/research/bqr7sm/global
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
